Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc  

(Public, LON:GSK)   Watch this stock  
Find more results forGSK
+3.08 (0.19%)
Jul 21 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,609.50 - 1,632.00
52 week 1,446.50 - 1,745.56
Open 1,628.00
Vol / Avg. 5.58M/7.25M
Mkt cap 80,075.56M*
P/E 47.62
Div/yield 19.00*
EPS 0.34*
Shares 4,918.42M
Beta     -
Inst. own     -
Jul 26, 2017
Q2 2017 GlaxoSmithKline PLC Earnings Call - 2:00pm BST - Add to calendar
Jul 26, 2017
Q2 2017 GlaxoSmithKline PLC Earnings Release - 11:00am BST - Add to calendar
Jul 19, 2017
Emergent BioSolutions Inc to Discuss Acquisition of Raxibacumab from GlaxoSmithKline PLC Conference Call - Webcast
May 22, 2017
GlaxoSmithKline PLC at UBS Global Healthcare Conference (One-on-One)
May 10, 2017
GlaxoSmithKline PLC at OBN's BioTrinity European Biopartnering and Investment Conference
May 4, 2017
GlaxoSmithKline PLC Annual Shareholders Meeting
May 3, 2017
GlaxoSmithKline plc Presents at Investment for Advanced Therapies Summit, May-03-2017 09:00 AM
May 3, 2017
GlaxoSmithKline PLC at Deutsche Bank Health Care Conference
Apr 26, 2017
Q1 2017 GlaxoSmithKline PLC Earnings Call - Webcast
Apr 26, 2017
Q1 2017 GlaxoSmithKline PLC Earnings Release

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 16.56% 3.81%
Operating margin 23.27% 9.32%
EBITD margin - 33.06%
Return on average assets 8.29% 1.89%
Return on average equity 295.67% 29.24%
Employees 99,827 -
CDP Score - A


980 Great West Road
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Officers and directors

Emma Walmsley Chief Executive Officer - Designate, Executive Director
Age: 46
Simon Dingemans Chief Financial Officer, Executive Director
Age: 52
Patrick Vallance President - Pharmaceuticals R&D, Executive Director
Roger Connor President - Global Manufacturing & Supply
Abbas Hussain President - Global Pharmaceuticals
Shah Abbas Hussain President - Global Pharmaceuticals
Luke Miels President - Global Pharmaceuticals
Daniel E Troy Senior Vice President, General Counsel
Claire Thomas Senior Vice President - Human Resources
Nick Hirons Senior Vice President – Global Ethics and Compliance